This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month
Why now
Thesis: Rival GLP-1 maintenance data pressures Lilly obesity share expectations.
Catalyst to watch: Further trial data and approvals.
Main risk: Single trial, competitive response.
Why it matters
Positive GLP-1 maintenance data for a rival drug pressures Lilly's obesity franchise share expectations.
Details
Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock is soaring.
Sources
- marketwatch · 2026-09-22 15:46 UTC